SANTA CLARA, Calif.,
March 30, 2011/PRNewswire/ --
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular
diagnostic solutions developer, announced today that the Company
has published a letter to shareholders.
Interested parties can read the letter at our website at:
Investor Message.
The letter is designed to provide key stakeholders with an
update regarding progress to date and management's objectives.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company
developing and marketing proprietary software platform technologies
to provide higher accuracy to, and increase the value of, the
standard 12-lead ECG. NewCardio's 3-D ECG software platform
reduces the time and expense involved in assessing cardiac status
while increasing the ability to diagnose clinically significant
conditions which were previously difficult to detect.
NewCardio's software products and services significantly
improve the diagnosis and monitoring of cardiovascular disease, as
well as cardiac safety assessment of drugs under development. For
more information, visit www.newcardio.com.
To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
